Botulinum Toxin

As an efficient neurotoxic protein produced by the bacterium Clostridium botulinum and related species, botulinum toxin, also known as botulinum neurotoxin (BoNT), can prevent the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, leading to flaccid paralysis. It can cause the disease botulism. It is also used in the commercialization of medical and cosmetics. There are seven main types of botulinum toxin, which are named as A to G types (A, B, C1, C2, D, E, F, and G). Among them, Type A and Type B botulinum toxin are more common, which can cause human diseases, and are also used in commerce and medicine. In contrast, types C-G are less common. Except for types E and F, which can cause diseases in humans, the other types can cause diseases in other animals.

Application of Botulinum Toxin

In recent times, commercial botulinum toxins produced by the bacterium Clostridium botulinum have been used in the cosmetics field (reducing facial wrinkles) and the medical field (muscle disorders, hidrosis, migraines). Among them, the approved and commercialized brand names for botulinum toxin A include Botox (onabotulinumtoxinA), Jeuveau (prabotulinumtoxinA), Xeomin/Bocouture (incobotulinumtoxinA), Dysport/Azzalure (abobotulinumtoxinA) and Letybo (letibotulinumtoxinA), and the approved brand name for botulinum toxin B is Myobloc (rimabotulinumtoxinB).

Recombinant type A botulinum toxins produced in Escherichia coli or yeast is undergoing pre-clinical and clinical trials research.

According to Frost & Sullivan, as a recombinant botulinum toxin candidate drug approved by the NMPA to undergo clinical trials for the improvement of moderate to severe glabellar lines, YY001 is the world's first and only clinical stage candidate for recombinant botulinum toxin type A. It is reported that YY001 has completed its phase II clinical trial, and a phase III clinical trial is being prepared.

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Recombinant Botulinum Toxin

• Microbial Strain Engineering and Screening
• Microbial Cell Banking (PCB/MCB/WCB)
• Upstream Process Development
• Downstream Process Development
• Formulation Development
• GMP Manufacturing
• Fill and Finish
• Analytical and Testing
• Regulatory Affairs

We are developing Recombinant Botulinum Toxin as an active substance or active pharmaceutical ingredient (API). The product is coming to market soon.